AI assistant
Tempest Therapeutics, Inc. — Director's Dealing 2014
Sep 25, 2014
34632_dirs_2014-09-25_4b8c2389-18d0-4768-bac3-ad6594f0b999.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2014-09-23
Reporting Person: Stock Harald F. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-09-23 | Common Stock | P | 522 | $14.2214 | Acquired | 13022 | Indirect |
Footnotes
F1: The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.21 to $14.48, inclusive. The Reporting Person undertakes to provide OvaScience, Inc., any security holder of OvaScience, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges sent forth in this footnote.
F3: By SB Vermogensverwaltungs KG, a trust of which the reporting person is a majority shareholder and managing partner.